Hemophilia A Stocks List

Hemophilia A Stocks Recent News

Date Stock Title
May 9 SGMO Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
May 9 SGMO Sangamo Therapeutics GAAP EPS of -$0.27 misses by $0.05, revenue of $0.48M misses by $5.88M
May 9 SGMO Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
May 9 SGMO Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
May 8 SGMO Sangamo Therapeutics Q1 2024 Earnings Preview
May 8 BAX Baxter International First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
May 8 BAX Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff
May 7 BAX Baxter to Present at Bank of America 2024 Health Care Conference
May 7 BAX Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
May 7 ALNY Alnylam Issues 2023 Corporate Responsibility Report
May 5 ALNY The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 3 ALNY Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
May 3 BAX Baxter International Inc. (NYSE:BAX) Q1 2024 Earnings Call Transcript
May 3 ALNY Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
May 3 ALNY Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
May 3 BAX The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy?
May 3 BAX Is There An Opportunity With Baxter International Inc.'s (NYSE:BAX) 46% Undervaluation?
May 3 ALNY Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
May 3 BAX Baxter International Inc (BAX) Q1 2024 Earnings Call Transcript Highlights: Strong Start with ...
Hemophilia A

Haemophilia A (or hemophilia A) is a genetic deficiency in clotting factor VIII, which causes increased bleeding and usually affects males. In the majority of cases it is inherited as an X-linked recessive trait, though there are cases which arise from spontaneous mutations.Factor VIII medication may be used to treat and prevent bleeding in people with haemophilia A.

Browse All Tags